Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EMERGENT BIOSOLUTIONS INC.

(EBS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EMERGENT BIOSOLUTIONS INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)

07/29/2021 | 04:32pm EDT

Item 2.02 Results of Operations and Financial Condition.

On July 29, 2021, Emergent BioSolutions Inc. (the "Company") announced financial and operating results for the three- and six-month periods ended June 30, 2021. The Company will also use presentation materials in connection with the conference call scheduled for the same day to discuss these results ("Earnings Call Slides"). Such presentation materials will be posted on the Company's website at www.emergentbiosolutions.com. Copies of the earnings press release and Earnings Call Slides are furnished as Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form 8-K, respectively, and are incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

The disclosure contained in Item 2.02 of this Current Report on Form 8-K is incorporated herein by reference.

Item 8.01 Other Events.

Also on July 29, 2021, the Company issued a press release announcing that the U.S. Food and Drug Administration is allowing the Company's Bayview manufacturing facility to resume production of Johnson & Johnson's Covid-19 vaccine bulk drug substance. A copy of that press release is attached hereto as Exhibit 99.3 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.                                               Description
99.1                          Earnings P    ress release issued by the Company on July 29, 2021.
99.2                          Earnings Call Slides, dated July 29, 2021.
99.3                          Press release issued by the Company on July 29, 2021.
                            Emergent BioSolutions Inc. Current Report on Form 8-K, dated July 29,
101                         2021 formatted in XBRL (Extensible Business Reporting Language): Cover
                            Page. The instance document does not appear in the Interactive Data File
                            because its XBRL tags are embedded within the Inline XBRL document.
                            Cover Page Interactive Data File (formatted as Inline XBRL and contained
104                         in Exhibit 101).

© Edgar Online, source Glimpses

All news about EMERGENT BIOSOLUTIONS INC.
09/14Calgary firm advances new trial, manufacturing of mRNA vaccine for COVID-19
AQ
09/14EMERGENT BIOSOLUTIONS : Signs Five-Year, $90 Million Contract With Providence Th..
MT
09/14EMERGENT BIOSOLUTIONS : Secures Multi-Year Development and Manufacturing Agreeme..
AQ
09/14Emergent BioSolutions Inc. Secures Multi-Year Development and Manufacturing A..
CI
09/13EMERGENT BIOSOLUTIONS : FDA - Coronavirus (COVID-19) Update
AQ
09/09EMERGENT BIOSOLUTIONS : Financial Statements and Exhibits (form 8-K/A)
AQ
08/25EMERGENT BIOSOLUTIONS : Launches Late-Stage Trial of Investigational COVID-19 Pl..
MT
08/25Emergent's COVID-19 plasma therapy to be tested in NIH-sponsored study
RE
08/25Emergent's COVID-19 therapy to be tested in NIH-sponsored study
RE
08/25EMERGENT BIOSOLUTIONS : rsquo; COVID-19 Human Immune Globulin Product Candidate ..
AQ
More news
Analyst Recommendations on EMERGENT BIOSOLUTIONS INC.
More recommendations
Financials (USD)
Sales 2021 1 797 M - -
Net income 2021 377 M - -
Net Debt 2021 152 M - -
P/E ratio 2021 8,28x
Yield 2021 -
Capitalization 3 068 M 3 068 M -
EV / Sales 2021 1,79x
EV / Sales 2022 1,77x
Nbr of Employees 2 200
Free-Float 88,6%
Chart EMERGENT BIOSOLUTIONS INC.
Duration : Period :
Emergent BioSolutions Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EMERGENT BIOSOLUTIONS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 57,14 $
Average target price 83,33 $
Spread / Average Target 45,8%
EPS Revisions
Managers and Directors
Robert G. Kramer President, Chief Executive Officer & Director
Richard Scott Lindahl Chief Financial Officer, Treasurer & Executive VP
Fuad El Hibri Executive Chairman
Sharon M. Solomon Chief Information Officer & Senior Vice President
Karen L. Smith Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
EMERGENT BIOSOLUTIONS INC.-36.23%3 068
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.20.81%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604